GREY:IPHAF - Post by User
Post by
labumbaon Feb 13, 2010 5:34pm
697 Views
Post# 16783676
from the mouth of Paladin CEO
from the mouth of Paladin CEOIsotechnika (TSX:ISA) has a drug called voclosporin, indicated for uveitis, an ocular disease, which left untreated leads to blindness. Other indications include psoriasis and transplantation.
In the ocular field, partner Lux Biosciences plans to file by the end of the first quarter of 2010 for marketing approvals in the U.S. and Europe to be the first oral treatment of modifying the course of uveitis, setting the stage for Isotechnika to receive milestone payments and royalties next year, Mr. Goodman says.
Isotechnika also plans to submit voclosporin for regulatory approval in Canada by mid-2010 as a treatment for psoriasis. The company is also looking for a partner to conduct two Phase 3 trials in transplantation. Mr. Goodman adds, “We think there is a lot of upside in the company.”
BEST PENNY STOCK IN TOWN ....
GO ISA GO